Navigation Links
Optimer Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
Date:12/16/2010

SAN DIEGO, Dec. 16, 2010 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) is scheduled to present at the 29th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco on Wednesday, January 12, 2011. Pedro Lichtinger, Optimer's President and Chief Executive Officer, will present at 8:30 a.m. Pacific Time (11:30 a.m. Eastern Time).

(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

A live audio webcast of this presentation will be accessible on the Investors page of the Company's website at www.optimerpharma.com. Replays of this presentation will be available at the same location for 30 days following the meeting.

About Optimer PharmaceuticalsOptimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing hospital specialty products to treat serious infections and address unmet medical needs. Optimer has two anti-infective product candidates in development, Fidaxomicin and Pruvel™ (prulifloxacin).  Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection (CDI).  The Company has submitted an NDA to the FDA, and filed a MAA with the EMA (Europe) for fidaxomicin. Pruvel™ is a prodrug in the fluoroquinolone class of antibiotics being developed as a treatment for infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.ContactsOptimer Pharmaceuticals, Inc.Christina Donaghy, Corporate Communications ManagerJohn D. Prunty, Chief Financial Officer & VP Finance858-909-0736Canale CommunicationsJason I. Spark, Senior Vice President619-849-6005
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Optimer Pharmaceuticals to Present at Oppenheimer Healthcare Conference
2. Optimer Pharmaceuticals Announces Presentations at Upcoming IDSA Annual Meeting
3. Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC
4. Optimer Pharmaceuticals Phase 3 Clinical Trials show Fidaxomicin is Superior to Vancomycin in Treatment of Recurrent Clostridium difficile Infection (CDI); Data Presented at ICAAC
5. Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
6. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
7. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
8. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
9. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
10. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
11. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... Prominent academics, leaders of the biopharmaceutical ... 3rd at Genetic Rx, a networking conference of ... place at the Joseph B. Martin Conference Center ... present and future of genetic medicines—including siRNA, ASOs, ... well as the treatment of patients with rare ...
(Date:11/22/2014)... (PRWEB) November 21, 2014 RURO, ... solutions provider, has released Limfinity® version 5.1.4. , ... projects of Limfinity® than ever in RURO’s 8 ... and minority framework enhancement. Limfinity® version 5.1.4 is ... above and beyond bug fixes! , Limfinity® 5.1.4 ...
(Date:11/22/2014)... The “Chiral Chromatography Columns Market by ... Glass, Plastic), by Application [GC, LC (HPLC, UHPLC, ... 2018” analyses and studies the major market drivers, ... Asia, and Rest of the World. , Browse ... through 135 pages and in-depth TOC on “Chiral ...
(Date:11/22/2014)... element of surprise has been a major advantage of ... Until now, epidemiologists had nothing to measure that might ... suboptimal responses to both the H1N1 pandemic of 2009 ... http://photos.prnewswire.com/prnh/20141121/160242 That virus advantage ... structural changes have been found that invariably to date ...
Breaking Biology Technology:Pioneering Academics and Key Industry Leaders to Discuss Rare Diseases and the Emergence of New Genetic Medicines at Genetic Rx on December 3rd 2RURO Announces Limfinity® version 5.1.4 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 3Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 4Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 5Viruses' Advantage of Surprise is Lost 2
... SOUTH SAN FRANCISCO, Calif., March 14 ,Exelixis, Inc. (Nasdaq: ... its option to further develop and commercialize Exelixis,compound XL518, ... currently,in a phase 1 clinical trial. Under the terms ... to be responsible for the phase,1 clinical trial until ...
... R.P. Baker Distinguished Professor of Physics at Rensselaer Polytechnic ... Materials Research Society (MRS). The MRS has recognized Lu ... specifically his seminal contributions to the fundamental understanding of ... that MRS has named a class of fellows. Lu ...
... ,Cellectis SA (NYSE: ALCLS ), a ... today that it filed a patent infringement ... States District Court for the,Eastern District of ... that,by making and selling certain meganucleases, Precision ...
Cached Biology Technology:Option to Develop Exelixis Compound Exercised By Genentech 2Option to Develop Exelixis Compound Exercised By Genentech 3Option to Develop Exelixis Compound Exercised By Genentech 4Professor Toh-Ming Lu named fellow of the Materials Research Society 2Cellectis Sues Precision BioSciences for Infringement of its Patents Concerning Meganuclease Technology 2Cellectis Sues Precision BioSciences for Infringement of its Patents Concerning Meganuclease Technology 3Cellectis Sues Precision BioSciences for Infringement of its Patents Concerning Meganuclease Technology 4
(Date:11/5/2014)... – Kelly Redmond has dedicated his career to ... to a general audience. , As deputy director ... Center at Nevada,s Desert Research Institute, Redmond has ... management, application and dissemination of climate data to ... Fall Meeting in San Francisco on December 15-19, ...
(Date:11/4/2014)... Fla. (November 4, 2014) — Think about the way ... How do neighboring cells know that they are supposed ... how do these tissues find the correct place and ... answering these crucial questions. , In a new study, ... to communicate with their surrounding neighbors, at the head-trunk ...
(Date:11/3/2014)... 2014 Research and Markets has announced ... Technologies, Markets and Companies" to their offering. ... methods, which have already started to play an important role ... replacing the old fashioned bone marrow transplants. Role of cells ... to become a part of medical practice. Stem ...
Breaking Biology News(10 mins):Nevada climatologist to be honored at AGU Fall Meeting for lifetime of public outreach 2The inside story: How the brain and skull stay together 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3
... far from a plodding Cretaceous era scavenger whose long tail only ... T. rex ,s athleticism (and its rear end) ... Scott Persons. His extensive research shows that powerful tail muscles made ... time. As Persons says, "contrary to earlier theories, ...
... molecules called microRNAs act together with hormones to control ... drugs might be able to prevent premature labor, researchers ... preclinical study. "With these findings, we understand better ... we might have the potential to manipulate it and ...
... PA, 15 November 2010 - A family history of Alzheimer,s ... a new study in Biological Psychiatry suggests that ... Alzheimer,s is the most common form of dementia in ... alone. In order to develop preventative treatments, it is necessary ...
Cached Biology News:T. rex's big tail was its key to speed and hunting prowess 2Tiny RNA molecules control labor, may be key to blocking premature birth 2Where did you get those eyes and that brain? 2
... scanning and positioning system is designed ... to be positioned or scanned with ... provides superior responsiveness compared to micropositioners ... (X or XY stage) are driven ...
For microscopy...
... The ULS cDNA Synthesis and Labeling Kit ... hybridization experiments. First unmodified cDNA is made ... cDNA using an Oligo(dT) primer. Unlike other ... used in the reverse transcription reaction. This ...
... 'The DNAscope LM is a high quality ... technology for optimal background rejection and spatial resolution. ... is the only low cost microarray scanner that ... excitation sources. Main Features: Includes ...
Biology Products: